Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$84.19 USD

84.19
1,856,690

+1.15 (1.39%)

Updated Sep 27, 2024 12:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sheraz Mian headshot

The Tech Sector's Strong Earnings Power

Technology sector's Q1 results are coming from a diverse cross-section of companies.

    BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?

    We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

      United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

      United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017

        What to Expect from Prothena (PRTA) This Earnings Season?

        Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.

          What's in Store for Merck (MRK) this Earnings Season?

          Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.

            Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?

            Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.

              What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?

              Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.

                Arpita Dutt headshot

                Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

                Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

                  Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?

                  Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.

                    Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?

                    Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.

                      Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?

                      Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

                        Celgene (CELG) to Post Q1 Earnings: What's in the Cards?

                        Celgene Corporation (CELG) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

                          What's in Store for Agenus (AGEN) this Earnings Season?

                          Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.

                            What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?

                            GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.

                              Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?

                              We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.

                                Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?

                                Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.

                                  Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?

                                  Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback

                                    Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.

                                      Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion

                                      Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.

                                        KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day

                                        KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day

                                          Kevin Cook headshot

                                          Bear of the Day: Gilead Sciences (GILD)

                                          Could a transformational M&A deal reverse the 18-month slide in sales and profits?

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug

                                            Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.

                                              Gilead (GILD) Up 4.3% Since Earnings Report: Can It Continue?

                                              Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                Galapagos Initiates 3 Phase II Studies for Filgotinib

                                                Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.

                                                  New Strong Sell Stocks for March 31st

                                                  Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: